Cargando…
Hydroxychloroquine reduces T cells activation recall antigen responses
BACKGROUND: In the context of the current COVID-19 pandemic, there is still limited information about how people suffering from autoimmune diseases respond to the different COVID vaccines. The fact that they are taking an immunosuppressant or other drugs that aim to decrease the immune system activi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395872/ https://www.ncbi.nlm.nih.gov/pubmed/37531383 http://dx.doi.org/10.1371/journal.pone.0287738 |
_version_ | 1785083674523336704 |
---|---|
author | Kowatsch, Monika M. Lajoie, Julie Mwangi, Lucy Omollo, Kenneth Oyugi, Julius Hollett, Natasha Kimani, Joshua Fowke, Keith R. |
author_facet | Kowatsch, Monika M. Lajoie, Julie Mwangi, Lucy Omollo, Kenneth Oyugi, Julius Hollett, Natasha Kimani, Joshua Fowke, Keith R. |
author_sort | Kowatsch, Monika M. |
collection | PubMed |
description | BACKGROUND: In the context of the current COVID-19 pandemic, there is still limited information about how people suffering from autoimmune diseases respond to the different COVID vaccines. The fact that they are taking an immunosuppressant or other drugs that aim to decrease the immune system activities, such as hydroxychloroquine (HCQ), could also impact their ability to respond to a COVID vaccine and vaccines in general. METHODS: Heathy donors were given 200mg of HCQ daily for 6-weeks to assess HCQs impact on the systemic T cells and humoral immune response. Peripheral blood mononuclear cells (PBMC) and plasma were obtained at baseline and 6-weeks after starting daily HCQ. Flow cytometry assays were designed to determine changes in T cell activation and T cell responses. Bead array multiplex were used to analyse antibodies and cytokine levels before and after HCQ intake. RESULTS: As anticipated, HCQ treatment decreased ex vivo T cell activation. We observed a decrease in CD4(+)CD161(-) expressing CCR5 (p = 0.015) and CD69 (p = 0.004) as well as in CD8(+)CCR5(+) (p = 0.003), CD8(+)CD161(+)CCR5(+) (p = 0.002) and CD8(+)CD161(+)CD95(+) (p = 0.004). Additionally, HCQ decreased the proportion of Th17 expressing CD29 (p = 0.019), a subset associated with persistent inflammation. The proportion of T regulatory cells expressing the inhibitory molecule TIGIT was also reduced by HCQ (p = 0.003). As well, T cells from people on HCQ were less responsive to activation and cytokine production following stimulation with recall antigens and memory T cells were less likely to produce both IFNγ and TNFα following stimulation. CONCLUSION: This study shows HCQ is associated with lower T cell activation and decreased T cell cytokine production. While this study was not performed with the intent of looking at COVID vaccine response, it does provide important information about the changes in immune response that may occur in patient taking HCQ as a treatment for their autoimmune disease. |
format | Online Article Text |
id | pubmed-10395872 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-103958722023-08-03 Hydroxychloroquine reduces T cells activation recall antigen responses Kowatsch, Monika M. Lajoie, Julie Mwangi, Lucy Omollo, Kenneth Oyugi, Julius Hollett, Natasha Kimani, Joshua Fowke, Keith R. PLoS One Research Article BACKGROUND: In the context of the current COVID-19 pandemic, there is still limited information about how people suffering from autoimmune diseases respond to the different COVID vaccines. The fact that they are taking an immunosuppressant or other drugs that aim to decrease the immune system activities, such as hydroxychloroquine (HCQ), could also impact their ability to respond to a COVID vaccine and vaccines in general. METHODS: Heathy donors were given 200mg of HCQ daily for 6-weeks to assess HCQs impact on the systemic T cells and humoral immune response. Peripheral blood mononuclear cells (PBMC) and plasma were obtained at baseline and 6-weeks after starting daily HCQ. Flow cytometry assays were designed to determine changes in T cell activation and T cell responses. Bead array multiplex were used to analyse antibodies and cytokine levels before and after HCQ intake. RESULTS: As anticipated, HCQ treatment decreased ex vivo T cell activation. We observed a decrease in CD4(+)CD161(-) expressing CCR5 (p = 0.015) and CD69 (p = 0.004) as well as in CD8(+)CCR5(+) (p = 0.003), CD8(+)CD161(+)CCR5(+) (p = 0.002) and CD8(+)CD161(+)CD95(+) (p = 0.004). Additionally, HCQ decreased the proportion of Th17 expressing CD29 (p = 0.019), a subset associated with persistent inflammation. The proportion of T regulatory cells expressing the inhibitory molecule TIGIT was also reduced by HCQ (p = 0.003). As well, T cells from people on HCQ were less responsive to activation and cytokine production following stimulation with recall antigens and memory T cells were less likely to produce both IFNγ and TNFα following stimulation. CONCLUSION: This study shows HCQ is associated with lower T cell activation and decreased T cell cytokine production. While this study was not performed with the intent of looking at COVID vaccine response, it does provide important information about the changes in immune response that may occur in patient taking HCQ as a treatment for their autoimmune disease. Public Library of Science 2023-08-02 /pmc/articles/PMC10395872/ /pubmed/37531383 http://dx.doi.org/10.1371/journal.pone.0287738 Text en © 2023 Kowatsch et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Kowatsch, Monika M. Lajoie, Julie Mwangi, Lucy Omollo, Kenneth Oyugi, Julius Hollett, Natasha Kimani, Joshua Fowke, Keith R. Hydroxychloroquine reduces T cells activation recall antigen responses |
title | Hydroxychloroquine reduces T cells activation recall antigen responses |
title_full | Hydroxychloroquine reduces T cells activation recall antigen responses |
title_fullStr | Hydroxychloroquine reduces T cells activation recall antigen responses |
title_full_unstemmed | Hydroxychloroquine reduces T cells activation recall antigen responses |
title_short | Hydroxychloroquine reduces T cells activation recall antigen responses |
title_sort | hydroxychloroquine reduces t cells activation recall antigen responses |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395872/ https://www.ncbi.nlm.nih.gov/pubmed/37531383 http://dx.doi.org/10.1371/journal.pone.0287738 |
work_keys_str_mv | AT kowatschmonikam hydroxychloroquinereducestcellsactivationrecallantigenresponses AT lajoiejulie hydroxychloroquinereducestcellsactivationrecallantigenresponses AT mwangilucy hydroxychloroquinereducestcellsactivationrecallantigenresponses AT omollokenneth hydroxychloroquinereducestcellsactivationrecallantigenresponses AT oyugijulius hydroxychloroquinereducestcellsactivationrecallantigenresponses AT hollettnatasha hydroxychloroquinereducestcellsactivationrecallantigenresponses AT kimanijoshua hydroxychloroquinereducestcellsactivationrecallantigenresponses AT fowkekeithr hydroxychloroquinereducestcellsactivationrecallantigenresponses |